Related Experiment Video
Updated: Mar 28, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
Mesenchymal stem cell-derived inflammatory fibroblasts mediate interstitial fibrosis in the aging heart
JoAnn Trial1, Mark L Entman2, Katarzyna A Cieslik1
1Division of Cardiovascular Sciences and the DeBakey Heart Center, Department of Medicine, Baylor College of Medicine, Houston, TX, United States.
Abstract:
Pathologic fibrosis in the aging mouse heart is associated with dysregulated resident mesenchymal stem cells (MSC) arising from reduced stemness and aberrant differentiation into dysfunctional inflammatory fibroblasts. Fibroblasts derived from aging MSC secrete higher levels of 1) collagen type 1 (Col1) that directly contributes to fibrosis, 2) monocyte chemoattractant protein-1 (MCP-1) that attracts leukocytes from the blood and 3) interleukin-6 (IL-6) that facilitates transition of monocytes into myeloid fibroblasts. The transcriptional activation of these proteins is controlled via the farnesyltransferase (FTase)-Ras-Erk pathway. The intrinsic change in the MSC phenotype acquired by advanced age is specific for the heart since MSC originating from bone wall (BW-MSC) or fibroblasts derived from them were free of these defects. The potential therapeutic interventions other than clinically approved strategies based on findings presented in this review are discussed as well. This article is a part of a Special Issue entitled "Fibrosis and Myocardial Remodeling".
Insights
Aging heart fibrosis stems from stem cell dysfunction. Aged mesenchymal stem cells (MSCs) differentiate into inflammatory fibroblasts, secreting collagen and inflammatory factors, driving cardiac fibrosis.
Area of Science:
- Cardiovascular Biology
- Stem Cell Biology
- Aging Research
Background:
- Pathologic fibrosis in aging hearts is linked to resident mesenchymal stem cells (MSCs).
- Aging impairs MSC stemness and promotes differentiation into dysfunctional inflammatory fibroblasts.
- These aged fibroblasts contribute to cardiac fibrosis and inflammation.
Purpose of the Study:
- To investigate the role of aging resident mesenchymal stem cells (MSCs) in cardiac fibrosis.
- To identify molecular mechanisms driving fibroblast dysfunction in aging hearts.
- To explore potential therapeutic targets for age-related cardiac fibrosis.
Main Methods:
- Analysis of resident mesenchymal stem cells (MSCs) from aging mouse hearts.
- Characterization of fibroblast differentiation and secretory profiles.
- Investigation of the farnesyltransferase (FTase)-Ras-Erk pathway.
Main Results:
- Aging MSCs exhibit reduced stemness and aberrant differentiation into inflammatory fibroblasts.
- These fibroblasts secrete elevated collagen type 1 (Col1), monocyte chemoattractant protein-1 (MCP-1), and interleukin-6 (IL-6).
- The FTase-Ras-Erk pathway mediates transcriptional activation of these fibrotic and inflammatory factors.
- Defects are specific to cardiac MSCs, not bone wall MSCs (BW-MSCs).
Conclusions:
- Dysfunctional aging cardiac MSCs drive fibrosis through inflammatory fibroblast activation.
- The FTase-Ras-Erk pathway is a key regulator of this process.
- Targeting this pathway may offer novel therapeutic strategies for age-related cardiac fibrosis.
Related Concept Videos
Introduction to Fibroblasts
Myocarditis I: Introduction
Extracellular Matrix
Heart Failure II: Pathophysiology

